June 3, 2019 / 5:26 AM / 3 months ago

BRIEF-Pharma Mar Says Lurbinectedin Achieves Positive Results In Phase II Trial For Treatment Of Small Cell Lung Cancer

June 3 (Reuters) - Pharma Mar S.A.:

* SAID ON SATURDAY LURBINECTEDIN ACHIEVED PRIMARY ENDPOINT OF OVERALL RESPONSE RATE (ORR) IN PHASE II TRIAL

* SAYS LURBINECTEDIN HAS BEEN SHOWN TO BE ACTIVE AS SINGLE AGENT IN SECOND LINE TREATMENT OF SMALL CELL LUNG CANCER

* ORR WAS 35.2% AND MEDIAN OVERALL SURVIVAL (OS) WAS 9.3 MONTHS

* LURBINECTEDIN HAS BEEN SEEN TO HAVE FAVOURABLE AND MANAGEABLE SAFETY

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below